Invista’s new 400 kilo-tonne-per-annum adiponitrile facility is expected to be integrated with the recently completed hexamethylenediamine plant and nylon 6,6 polymer facility to produce nylon 6,6 and other high-value products in China.

Siluria Technologies, a pioneer in the commercial production of fuels and chemicals made from clean and abundant natural gas, and The Linde Group, a world-leading gases and engineering company, announced that they have entered into a collaboration agreement.

The move to acquire Mahoney Environmental is in line with Neste’s growth strategy and will enable the company to strengthen its position in renewable raw material sourcing. The deal will also act as a platform for the firm to grow its raw material supply chain in North America.

Located in Omsk, the modern oil-refining catalyst-production facility is expected to produce 21,000 tonnes of modern catalysts which will be used for deep oil refining and production of Euro-5 fuels. The project has also been regarded as a national project by Russia.

As an emergency measure during the coronavirus pandemic in France, Arkema will be manufacturing the alcohol-based solution per week and supplying it to hospitals in the European country for free.

Sartorius was once again a double award winner at the Fisher Scientific European Sales Conference in Karpacz, Poland, retaining the same awards won in 2018, European Excellence and Supplier Best Booth.

The Weylchem Group of Companies will be investing the mammoth amount at its Weylchem Lamotte site in France. The company plans to use the investment for upgrading the site’s equipment and improving the Speciality Chemicals Assets.

The key growth drivers for the fertiliser market are increasing awareness about food security in developed counties and population growth, states the Global Market Insights report. It further adds that Latin America and Asia-Pacific will provide significant growth impetus in terms of revenue.

Sartorius Stedim Biotech (SSB) and Novasep have recently entered into a collaboration agreement in the area of chromatography and single-use bioprocessing.

AGC has plans to purchase all the shares of Molecular Medicine (Molmed) for 262 million dollars via a voluntary tender offer. The move is also supported by Fininvest, the largest shareholder in the Italian company.